After a positive evaluation by Palmetto GBA, CMS has approved coverage of the molecular diagnostic to predict risk of recurrence and drug therapy benefit in breast cancer patients.
Diagnostic applications of liquid biopsy as precision medicine technology in cancer and organ transplantation explored at Digital PCR Conference
One of the largest insurance companies in the United States, Highmark has announced it will begin providing coverage of the VeriStrat assay to guide second-line treatment decisions for patients with non-small cell lung cancer. Coverage takes effect on October 27, 2014.
CMS has agreed to provide reimbursement coverage for Exact Sciences’ first-mover FDA-approved noninvasive stool DNA screening test for colorectal cancer.
A new multi-year, multi-investigator research collaboration will accelerate the translation of genomic discoveries into clinical diagnostics in oncology.
Under a new grant from the National Cancer Institute, Advanced Cell Diagnostics will partner with the Cleveland Clinic to develop an ultrasensitive diagnostic test for B-cell lymphoma.
Recent research suggests that tumor cells circulating in the blood of metastatic patients could give as accurate a genomic read-out as tumor biopsies.
At the ASCP annual meeting, a panel of healthcare experts will focus on changes in the regulatory, compliance, and billing environment for pathology professionals.
An MD Anderson study identifies a genetic variant near the KLK3 gene that could stratify GS7 prostate cancer patients.
The acquisition of Sentilus strengthens Immucor’s transfusion diagnostics portfolio with microarray-based, next-generation technology.